Skip to content

Assessment of the complex polysaccharide's tumor regulation in Human Feeding Trials

Assessment of the complex polysaccharide's tumor regulation in Human Feeding Trials

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018188
Enrollment
Unknown
Registered
2018-09-04
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Group 1:Oral test sample 1 for 28 consecutive days.
Group 2:Oral test sample 2 for 28 consecutive days
Group 3:Oral positive samples for 28 consecutive days

Sponsors

Guangzhou Hongyun Medical Scientific and Technological Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Clear diagnosis of malignancies 2. Aged between 18-70 years male and female; 3. The expected survival period is more than 1 years; 4. The physical condition is good, and the Karnofsky (KPS) score is more than 80 points; 5. Tumor types are one of the following: lung cancer, stomach cancer, liver cancer, esophageal cancer, colorectal cancer, pancreatic cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer; 6. The clinical data is complete and with high compliance; 7. All participants and their family sign informed consent after told study details.

Exclusion criteria

Exclusion criteria: 1. Inconformity to above inclusive criteria; 2. Comply with severe heart, lung, kidney and liver dysfunction; 3. Comply with immune system and hematopoietic diseases; 4. Intracranial metastasis of malignant tumor; 5. Comply with complication such as gastrointestinal bleeding or intestinal obstruction; 6. Frequent vomiting; 7. Comply with severe infections; 8. Comply with psychological and behavioral abnormalities; 9. Pregnant or lactating women; 10. Severe cancer pain can not be effectively control; 11. Allergic or allergic to multiple drugs; 12. Received other similar treatment such as immunomodulatory drugs; 13. Participated in other similar clinical researchers.

Design outcomes

Primary

MeasureTime frame
Tumor markers;Diagnostic chip on immunologic cytokines;T lymphocyte subsets;Immunoglobulin;

Secondary

MeasureTime frame
KPS score;body weight;TCM symptom rating scale;

Countries

China

Contacts

Public ContactYAN QUNCHAO

Guangzhou Hongyun Medical Scientific and Technological Co.,Ltd.

yqunchao@163.com+86 13902283853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026